Bridging the innovation gap: Scalable cell therapies, adapti...

Biotech must build manufacturing and trial models that make cell therapies scalable, accessible & commercially viable.

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Key lessons from EHA 2026: Translating evidence into impact

Across four days in Sweden, EHA 2026 offered a clear view of the future of blood cancer care.

Establishing ctDNA as a validated primary surrogate endpoint

Circulating tumour DNA (ctDNA) has emerged as a promising primary surrogate endpoint in solid tumour oncology.

Early diagnosis means little without timely treatment

Early diagnosis only changes outcomes if it is followed by timely treatment.

ASCO 2026: Astellas innovates in ADCs and T Cell engagers, w...